The headlines may sound too good to be true however that’s exactly what an Israeli company is planning to do, as their novel eye drops passed the Phase 2b clinical trial earlier this month that showed promising results in patients with farsightedness, an inability to see or read nearby objects.
Israeli based Orasis, Pharmaceuticals, revealed the details of the latest results of the Phase 2b study for their CSF-1 eye drops which provided temporary relief from farsightedness, usually lasting for a few hours.
The study was based on results from 166 participants across several research centers in the US which tested both the efficacy and the safety of the eye drops and according to Elad Kedar, the CEO of Orasis, the results look promising both on the efficacy and safety parameters and could soon enter phase 3 of their testing.
Kedar noted that their eye drops do not contain anything new other than the chemicals that are already there in the market coupled with the fact that their eye drops have chemicals in low concentrations in comparison with the others make their product even more reliable. Also, patients have shown improvement by three eye chart lines, which is the standard requirement by FDA for these studies.
They don’t claim that their eye drops are a panacea for all kinds of farsightedness, but they specifically target age related farsightedness, known as presbyopia.
Dr. Eve J. Higginbotham, SM, MD, a professor of ophthalmology at the Perelman School of Medicine, Pennsylvania, is aware of the pitfalls when the patients assume responsibility for administering their own treatments and opines that there may be few people who would administer these drops sedulously two times a day, but many wouldn’t.
Farsightedness is usually attributed to the loss of elasticity in the eye lens as people age and these eye drops are intended to restore the ability of the eye lens to assume a spherical shape and consequently be able to see things clearly up close.
Orasis also confirmed that their drops intend to contract the pupil enough so that the patients regain enough focus, depth perception and clarity.
Though this treatment could work effectively, most people still prefer glasses to correct the condition and hence the question raises as to the viability of the product in the market.
Ideally, these drops can target people who are averse to both contact lenses and glasses and also to those who are in their early 40s who are in the beginning stage of needing reading glasses to obtain better focus but are reluctant to do so however as they age they would require stronger dosage. It’s left to see if these drops can keep up with the needs of the patients.
Kedar is sanguine about the product entering the market soon as they are well prepared to start their phase 3 testing soon enough.